S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
The potential of myocardial perfusion scintigraphy for risk stratification of asymptomatic patients with type 2 diabetes.
TL;DR: Single-photon emission computed tomography, stress echocardiography, and possibly EBCT or multi-slice computed tomographic, are emerging as valuable diagnostic tools for identifying asymptomatic diabetic patients who might require early and aggressive intervention to manage their cardiovascular risk.
Journal ArticleDOI
Oral Agents for Type 2 Diabetes: An Update
Bonnie Kimmel,Silvio E. Inzucchi +1 more
TL;DR: This article reviews published clinical trial data and places them into the context of contemporary, rational therapeutic strategies for this increasingly common condition.
Journal ArticleDOI
Improving glycemic control in the cardiothoracic intensive care unit: Clinical experience in two hospital settings ☆
Philip A. Goldberg,Olga V. Sakharova,Peter W. Barrett,Lillian N. Falko,Maureen G. Roussel,Leigh B. Bak,Dawn Blake-Holmes,Norman J. Marieb,Silvio E. Inzucchi +8 more
TL;DR: The IIP safely and effectively improved glycemic control in 2 CTICUs, with minimal hypoglycemia, and should help to reduce morbidity and mortality in CTICU patients.
Journal ArticleDOI
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
James P. Curtain,Kieran F. Docherty,Pardeep S. Jhund,Mark C. Petrie,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Olof Bengtsson,Anna Maria Langkilde,Mikaela Sjöstrand,Scott D. Solomon,John J.V. McMurray +15 more
TL;DR: In this paper, the effect of dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection fraction (HFrEF) was examined using Cox proportional hazards models.
Journal ArticleDOI
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
Matteo Serenelli,Matteo Serenelli,Michael Böhm,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Scott D. Solomon,David L. DeMets,Olof Bengtsson,Mikaela Sjöstrand,Anna Maria Langkilde,Inder S. Anand,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Mirta Diez,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Subodh Verma,Kieran F. Docherty,Pardeep S. Jhund,John J.V. McMurray +28 more
TL;DR: Dapagliflozin had a small effect on SBP in patients with HFrEF and was superior to placebo in improving outcomes, and well tolerated, across the range of SBP included in DAPA-HF.